Consistent with the role of SHP2 in the RTK/RAS/MAPK cascade, SHP2-AIs exhibit broad antitumor activity in RAS-dependent cancer models, such as those harboring RTK alterations and certain RAS and RAF mutations (23, 25, 28). The gene discussed is PTPN11; the disease is cancer.